Sign In

Marinna Madrid

Co-Founder at Cellino

Marinna Madrid, PhD, is the Co-Founder and Chief Product Officer at Cellino, a venture capital-backed biotech company focused on making personalized regenerative medicines economically viable at scale.12 She received her PhD and MA in Applied Physics from Harvard University, where she co-invented laser-based intracellular delivery techniques.2 Madrid obtained her BSc in Biophysics from the University of California, Los Angeles, after transferring from Riverside Community College.2

At Cellino, Madrid is working on developing an AI-powered laser editing platform to scale the production of stem cell-derived therapies.3 The company secured $16 million in seed financing in late 2023 to support this endeavor.3

Madrid's achievements include:

  1. Being named on the Forbes 30 Under 30 list for Healthcare in 201912
  2. Receiving the Harvard Graduate Prize Fellowship and the Catalyst Accelerator Grant from Harvard Medical School2
  3. Winning first place in competitions such as the SPIE Startup Challenge and TechCrunch Disrupt4

Before her success in biotech, Madrid initially studied journalism at NYU but later found her passion for science at a community college.5 Her experience spans various fields, including biophysics, food science, and physics education research.4 Madrid is also an advocate for STEM education and has been involved in mentoring programs to increase diversity in STEM fields.4

Highlights

Jul 17 · linkedin

🚨📢I’m thrilled to announce the publication of this long-awaited white paper in Cytotherapy on considerations for the development of iPSC-derived cell therapies!! A huge thanks to Bar Makovoz, PhD of the Cellino team and the fabulous JSRM-ISCT iPSC Committee for the extensive collaboration in developing this piece.

iPSC-derived cell therapies have incredible potential for treating and potentially curing a wide range of chronic degenerative conditions, but to reach patients at scale, the modality must overcome challenges like complex manufacturing processes, meticulous QA measures, high production costs, and a patchwork of regulatory standards. In this white paper, we explore:

🔹An overview of the required elements to develop autologous and allogeneic iPSC-derived cell therapies 🔹 Global regulatory guidance for development of iPSC-derived cell therapies across the US, UK, Japan, Australia, and the EU  🔹 Challenges facing widespread adoption of cell therapies, along with opportunities to automate iPSC manufacturing to expand access for patients  🔹 And much more!

📰Check out the article at https://lnkd.in/ef94AQiP Let’s keep moving personalized cell therapies forward to benefit patients!

cc ISCT, International Society for Cell & Gene Therapy, Uma Lakshmipathy, Xiaokui Zhang, PhD, Kapil Bharti, Dominic Wall, Yoji Sato, George Muschler, Anthony Ting, Nathan Smith, Shin Kawamata, Stephen Sullivan, PhD, MBA, FRSM, Arwa Z. Al-Riyami FRCPC, MD, BSc, Veronica Falco

#RegenerativeMedicine #CellTherapies #Patients #Biomanufacturing #Manufacturing #Autologous #Automation #Regulatory #Innovation #YourCellsYourCure

Related Questions

What are some of Marinna Madrid's most notable achievements at Cellino?
How did Marinna Madrid's work at Harvard influence her career in biotech?
What is the significance of Marinna Madrid's laser-based intracellular delivery techniques?
How did Marinna Madrid transition from journalism to a career in biotech?
What are the main goals of Cellino under Marinna Madrid's leadership?
Marinna Madrid
Marinna Madrid, photo 1
Marinna Madrid, photo 2
Add to my network

Location

Cambridge, Massachusetts